vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and SHENANDOAH TELECOMMUNICATIONS CO (SHEN). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $91.6M, roughly 2.0× SHENANDOAH TELECOMMUNICATIONS CO). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -5.9%, a 19.2% gap on every dollar of revenue. On growth, SHENANDOAH TELECOMMUNICATIONS CO posted the faster year-over-year revenue change (7.2% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-78.6M). Over the past eight quarters, SHENANDOAH TELECOMMUNICATIONS CO's revenue compounded faster (15.0% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Shenandoah Telecommunications Co is a U.S. regional telecom provider offering broadband internet, wireless voice/data services, digital cable TV, and fiber-optic solutions. It serves residential, small business and enterprise clients across Mid-Atlantic states, focusing on underserved rural and suburban markets in Virginia, West Virginia, Maryland and Pennsylvania.
AMPH vs SHEN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $91.6M |
| Net Profit | $24.4M | $-5.4M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -1.0% |
| Net Margin | 13.3% | -5.9% |
| Revenue YoY | -1.8% | 7.2% |
| Net Profit YoY | -35.7% | -95.8% |
| EPS (diluted) | $0.51 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $91.6M | ||
| Q3 25 | $191.8M | $89.8M | ||
| Q2 25 | $174.4M | $88.6M | ||
| Q1 25 | $170.5M | $87.9M | ||
| Q4 24 | $186.5M | $85.4M | ||
| Q3 24 | $191.2M | $87.6M | ||
| Q2 24 | $182.4M | $85.8M | ||
| Q1 24 | $171.8M | $69.2M |
| Q4 25 | $24.4M | $-5.4M | ||
| Q3 25 | $17.4M | $-9.4M | ||
| Q2 25 | $31.0M | $-9.0M | ||
| Q1 25 | $25.3M | $-9.1M | ||
| Q4 24 | $38.0M | $-2.7M | ||
| Q3 24 | $40.4M | $-5.3M | ||
| Q2 24 | $37.9M | $-12.9M | ||
| Q1 24 | $43.2M | $214.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -1.0% | ||
| Q3 25 | 13.2% | -8.0% | ||
| Q2 25 | 24.2% | -10.3% | ||
| Q1 25 | 21.9% | -6.9% | ||
| Q4 24 | 24.2% | -6.7% | ||
| Q3 24 | 29.8% | -4.8% | ||
| Q2 24 | 30.3% | -18.5% | ||
| Q1 24 | 27.9% | -4.0% |
| Q4 25 | 13.3% | -5.9% | ||
| Q3 25 | 9.0% | -10.5% | ||
| Q2 25 | 17.8% | -10.2% | ||
| Q1 25 | 14.8% | -10.4% | ||
| Q4 24 | 20.4% | -3.2% | ||
| Q3 24 | 21.1% | -6.0% | ||
| Q2 24 | 20.8% | -15.0% | ||
| Q1 24 | 25.1% | 310.0% |
| Q4 25 | $0.51 | $-0.13 | ||
| Q3 25 | $0.37 | $-0.20 | ||
| Q2 25 | $0.64 | $-0.19 | ||
| Q1 25 | $0.51 | $-0.19 | ||
| Q4 24 | $0.74 | $-0.34 | ||
| Q3 24 | $0.78 | $-0.13 | ||
| Q2 24 | $0.73 | $-0.24 | ||
| Q1 24 | $0.81 | $4.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $27.3M |
| Total DebtLower is stronger | $608.7M | $642.4M |
| Stockholders' EquityBook value | $788.8M | $880.8M |
| Total Assets | $1.6B | $1.9B |
| Debt / EquityLower = less leverage | 0.77× | 0.73× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $27.3M | ||
| Q3 25 | $276.2M | $22.6M | ||
| Q2 25 | $231.8M | $29.1M | ||
| Q1 25 | $236.9M | $87.5M | ||
| Q4 24 | $221.6M | $46.3M | ||
| Q3 24 | $250.5M | $43.1M | ||
| Q2 24 | $217.8M | $43.8M | ||
| Q1 24 | $289.6M | $389.7M |
| Q4 25 | $608.7M | $642.4M | ||
| Q3 25 | $608.6M | $535.4M | ||
| Q2 25 | $607.7M | $513.1M | ||
| Q1 25 | $603.9M | $515.8M | ||
| Q4 24 | $601.6M | $418.0M | ||
| Q3 24 | $596.4M | $345.2M | ||
| Q2 24 | $586.9M | $297.4M | ||
| Q1 24 | $594.0M | $298.7M |
| Q4 25 | $788.8M | $880.8M | ||
| Q3 25 | $776.7M | $892.7M | ||
| Q2 25 | $757.5M | $902.0M | ||
| Q1 25 | $751.3M | $910.5M | ||
| Q4 24 | $732.3M | $918.6M | ||
| Q3 24 | $727.7M | $925.4M | ||
| Q2 24 | $713.3M | $933.1M | ||
| Q1 24 | $672.4M | $871.6M |
| Q4 25 | $1.6B | $1.9B | ||
| Q3 25 | $1.7B | $1.9B | ||
| Q2 25 | $1.6B | $1.8B | ||
| Q1 25 | $1.6B | $1.8B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.4B |
| Q4 25 | 0.77× | 0.73× | ||
| Q3 25 | 0.78× | 0.60× | ||
| Q2 25 | 0.80× | 0.57× | ||
| Q1 25 | 0.80× | 0.57× | ||
| Q4 24 | 0.82× | 0.46× | ||
| Q3 24 | 0.82× | 0.37× | ||
| Q2 24 | 0.82× | 0.32× | ||
| Q1 24 | 0.88× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $28.8M |
| Free Cash FlowOCF − Capex | $24.6M | $-78.6M |
| FCF MarginFCF / Revenue | 13.4% | -85.8% |
| Capex IntensityCapex / Revenue | 4.5% | 117.2% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-257.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $28.8M | ||
| Q3 25 | $52.6M | $30.7M | ||
| Q2 25 | $35.6M | $20.9M | ||
| Q1 25 | $35.1M | $20.5M | ||
| Q4 24 | $29.0M | $20.6M | ||
| Q3 24 | $60.0M | $24.3M | ||
| Q2 24 | $69.1M | $2.5M | ||
| Q1 24 | $55.3M | $15.2M |
| Q4 25 | $24.6M | $-78.6M | ||
| Q3 25 | $47.2M | $-51.4M | ||
| Q2 25 | $25.0M | $-65.3M | ||
| Q1 25 | $24.4M | $-62.7M | ||
| Q4 24 | $16.6M | $-72.0M | ||
| Q3 24 | $46.2M | $-51.3M | ||
| Q2 24 | $63.1M | $-78.3M | ||
| Q1 24 | $46.5M | $-54.9M |
| Q4 25 | 13.4% | -85.8% | ||
| Q3 25 | 24.6% | -57.2% | ||
| Q2 25 | 14.3% | -73.7% | ||
| Q1 25 | 14.3% | -71.3% | ||
| Q4 24 | 8.9% | -84.3% | ||
| Q3 24 | 24.1% | -58.5% | ||
| Q2 24 | 34.6% | -91.3% | ||
| Q1 24 | 27.1% | -79.3% |
| Q4 25 | 4.5% | 117.2% | ||
| Q3 25 | 2.8% | 91.4% | ||
| Q2 25 | 6.1% | 97.3% | ||
| Q1 25 | 6.3% | 94.7% | ||
| Q4 24 | 6.7% | 108.4% | ||
| Q3 24 | 7.2% | 86.2% | ||
| Q2 24 | 3.3% | 94.2% | ||
| Q1 24 | 5.1% | 101.2% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 0.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SHEN
| Residential And SMB Incumbent Broadband | $41.5M | 45% |
| Residential And SMB Glo Fiber Expansion Markets | $23.0M | 25% |
| Commercial Fiber | $20.3M | 22% |
| RLEC Other | $6.8M | 7% |
